Original Article
The involvement and possible mechanism of NR4A1 in chondrocyte apoptosis during osteoarthritis

Xinge Shi1*, Hui Ye2,3*, Xuedong Yao3, Yanzheng Gao1

1Department of Orthopedics, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan, China; 2Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Academy of Orthopedics, Guangzhou 510665, Guangdong Province, China; 3Department of Orthopedics, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China. *Equal contributors.

Received October 26, 2016; Accepted January 11, 2017; Epub February 15, 2017; Published February 28, 2017

Abstract: Osteoarthritis (OA) is a joint disease caused by the breakdown of joint cartilage and underlying bone, and places great burdens to daily life of patients. Nuclear orphan receptor nuclear receptor subfamily 4, group A, member 1 (NR4A1) is vital for cell apoptosis, but little is known about its role in OA. This study aims to reveal the expression and function of NR4A1 during OA chondrocyte apoptosis. NR4A1 expression by qRT-PCR and western blot, and chondrocyte apoptosis by TUNEL assay were detected in normal and OA joint cartilage. NR4A1 was located in cartilage sections by immunohistofluorescence. Chondrocytes from normal joint cartilage were cultured in vitro for interleukin 6 (IL6) or tumor necrosis factor (TNF) treatment and si-NR4A1 transfection, after which the possible mechanism involving NR4A1 was analyzed. Results showed that NR4A1 expression and chondrocyte apoptosis were significantly elevated in OA cartilage (P < 0.05 and P < 0.01). NR4A1 was located in nuclei of normal cartilage chondrocytes, but was translocated to mitochondria and co-located with B-cell lymphoma 2 in OA chondrocytes. NR4A1 expression in cultured chondrocytes could be promoted by both IL6 and TNF treatment. si-NR4A1 partly reduced TNF-induced cell apoptosis. Inhibiting p38 by SB203580 could decrease TNF-induced NR4A1 to some extent, while inhibiting JNK could not. So NR4A1 is likely to facilitate OA chondrocyte apoptosis, which is associated with p38 MAPK and mitochondrial apoptosis pathway. This study provides a potential therapeutic target for OA treatment and offers information for regulatory mechanisms in OA.

Keywords: Osteoarthritis, NR4A1, tumor necrosis factor, mitochondrial apoptosis pathway, p38

Introduction

Osteoarthritis (OA), also known as degenerative arthritis or degenerative joint disease, is caused by breakdown of joint cartilage and underlying bone due to aging, joint injury or inherited factors. The incidence of OA, especially knee and hip OA, increases in the elderly [1], but recent studies have revealed growing OA incidence in younger adults and the annual newly diagnosed cases are nearly 9 in 1000 adults in England, Canada, Netherlands and Spain [2]. Significant correlation between chondrocyte apoptosis and OA grade has been reported [3], thus elevated chondrocyte apoptosis is a primary feature of OA. Impaired chondrocytes induce release of reactive oxygen species (ROS) [4] and activate production of inflammatory factors such as tumor necrosis factor (TNF) and interleukins (ILs) which in turn help to aggravate chondrocyte apoptosis [5, 6]. Alleviation of OA mainly relies on exercise, joint protectors and anti-inflammation drugs. Besides, artificial joint replacement is applicable to certain patients in advanced stages.

Research on the molecular mechanism of OA is a rapidly developing area in recent years, whereby several pivotal regulators and potential therapeutic target in OA development have been uncovered, such as nuclear factor κB [7], metalloproteinases [8], some microRNAs [9] and mitogen-activated protein kinase (MAPK) pathways [10]. Nuclear receptor subfamily 4, group A, member 1 (NR4A1), also known as nuclear orphan receptor TR3 or Nur77, is an important transcription factor whose transcription activity stimulates pathologic angiogenesis and thus facilitates wound healing [11, 12]. It also plays pivotal roles in regulating cell apopto-
NR4A1 is a target for treating OA

sis via interacting with proteins on mitochondria and activating mitochondrial apoptosis pathway [13]. However, little is known about its roles in OA.

This study aims at revealing the expression and function of NR4A1 in OA, especially its regulatory role in chondrocyte apoptosis. We assessed chondrocyte apoptosis and NR4A1 expression in normal and OA joint cartilage. Location of NR4A1 in these tissue sections were observed after immunohistofluorescence. Articular chondrocytes from normal cartilage were isolated and cultured for TNF or IL6 treatment and si-NR4A1 transfection to investigate the underlying mechanism of NR4A1 in modulating chondrocyte apoptosis. These results will help to understand the specific role of NR4A1 in chondrocyte apoptosis and offer a promising therapeutic target for OA treatment.

Material and methods

Tissue sampling

Human joint cartilage tissues were collected from 5 male (23 to 51 years old, 39.6 ± 5.07) and 5 female (27 to 50 years old, 39.8 ± 4.35) OA patients undergoing total knee replacement surgery from March 2014 to March 2015. Normal joint cartilage tissues were collected from 5 male (25 to 50 years old, 37.0 ± 5.32) and 5 female (23 to 49 years old, 35.6 ± 4.77) patients with amputation from accidents. No significant difference in age existed between genders or groups. The tissue samples were immediately stored at -80°C for RNA and protein extraction. A part of fresh tissues were quickly frozen in liquid nitrogen for production of frozen sections. The patients were informed of the sampling procedures before surgery, and the whole procedures were performed under the instructions of our institute.

Cell isolation, culture and treatment

Articular chondrocytes in joint cartilage from normal patients were isolated according to the description in previous studies [14, 15] with minor changes. Briefly, the cartilage tissues were cut into pieces, washed in phosphate buffered saline (PBS) for five times, and digested in 0.25% trypsin (Gibco, Carlsbad, CA) for 30 min at 37°C. The cells were washed in PBS again and digested in collagenase II (Sigma-Aldrich, Shanghai, China) for 4 h at 37°C. Then the suspension was filtered and cells were collected, washed in PBS and resuspended in Dulbecco’s modified Eagle medium-F12 supplemented with 10% fetal bovine serum (Gibco). The cells were adjusted to 1 × 10⁴/mL and cultured in humidified atmosphere with 5% CO₂ at 37°C. The medium was changed every 48 h and the cells were passaged at a confluence of 90%.

IL6 and TNF treatment in chondrocytes was performed based on a previous study [16]. Human recombinant IL6 or TNF (PeproTech, Rocky Hill, NJ) was added to the medium to a final concentration of 100 ng/mL and the cells were treated for 12 or 24 h until further analysis. Cells were then treated with SB203580 (a selective inhibitor of p38 MAPK) or SP600125 (a selective inhibitor of JNK, Calbiochem, Boston, MA) at a concentration of 10 µM for 24 h according to previous description [17, 18]. The same amount of dimethylsulfoxide was added as control.

Cell transfection

NR4A1-specific siRNA and scrambled control siRNA were synthesized by RiboBio (Guangzhou, China) and transfected in cultured chondrocytes with the mediation of Lipofactamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 1 × 10⁴ cells were transfected with 1 pmol siRNA in each well of 96-well plates, and incubated at 37°C for 48 h until further analysis.

TUNEL assay

Apoptotic cells in tissue sections or cultured cells were detected by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method using One-step TUNEL Cell Apoptosis Assay Kit-FITC (Solarbio, Beijing, China) according to the manufacturer’s instructions. The frozen sections or cell smears were fixed in 4% paraformaldehyde for 1 h, washed in PBS twice and incubated on ice with 1% Triton-X 100 (Solarbio) for 2 min. Then new-made TUNEL detection buffer was added to the section for 1-h-incubation in dark at 37°C. Cell nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich). After washed in PBS, the sections were mounted and observed under a fluorescence microscope (Olympus,
NR4A1 is a target for treating OA

Tokyo, Japan). The apoptotic cell number was counted in randomly-selected view fields.

**Immunohistofluorescence**

The frozen sections (8 μm) of tissues were used for the localization of NR4A1 according to the commonly used procedure. Briefly, the sections were blocked in 10% bovine serum albumin (Sigma-Aldrich) for 1 h at room temperature and incubated in primary antibodies for NR4A1 (ab109180) or B-cell lymphoma 2 (BCL2, ab32124, Abcam, Cambridge, UK) at 1:200 dilution for 1 h at room temperature. After washed in PBS, the sections were incubated in secondary antibodies Alexa Fluor 647 (ab62050) or Alexa Fluor 488 (ab150073) at 1:200 for 1 h in dark at room temperature. The primary antibodies anti-prohibitin (PHB, ab-75771) were used to mark mitochondria. The nuclei were stained by DAPI. Then the sections were washed three times with PBS, mounted and observed by a fluorescence microscope (Olympus).

**Real-time quantitative PCR**

Tissue samples were extracted in Trizol (Invitrogen) for total RNA extraction. DNA or protein contamination was removed by RNA Purification Kit (TIANGEN, Beijing, China) and then 1 μg RNAs of each sample were used for complementary DNAs (cDNAs) synthesis by the catalysis of PrimeScript Reverse Transcriptase (Takara, Dalian, China). qRT-PCR was conducted on QuantStudio 6 Flex Realtime PCR System (Applied Biosystems, Carlsbad, CA) with 20 ng template cDNAs and the specific primer for human NR4A1 (Fw: 5’-CAG CTT GCT TGT CGA TGT C-3’ and Rv: 5’-GTG TCC ATG AAG ATC TTG TCA ATG-3’), Gapdh (Fw: 5’-GAA GGT GAA GGT CGG AGT C-3’ and Rv: 5’-GAA GAT GGT GAT GGG ATT TG-3’) was used as an internal reference. Data were analyzed by the 2^{-ΔΔCt} method.

**Western blot**

Protein of tissues and cultured cells was extracted by M-Per Mammalian Protein Extraction Reagent (Thermo Scientific, Carlsbad, CA) according to the manufacturer’s instructions. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted on a polyvinylidene fluoride membrane. The membrane was blocked in 5% skim milk for 2 h at room temperature and incubated in the primary antibodies (1:800) for NR4A1 (ab109180) or cleaved poly (ADP-ribose) polymerase 1 (PARP1, ab4830) at 4°C overnight. GAPDH (ab181602) was used as an internal reference. After washed in PBS, the membrane was incubated in the horse reddish peroxidase-conjugated secondary antibodies (1:2000) for 1 h at room temperature. Then positive signals were developed by EasyBlot ECL Kit (Sangon Biotech, Shanghai, China) and the grey scale was analyzed by software ImageJ 1.49 (National Institute of Health, Bethesda, MD).
**NR4A1 is a target for treating OA**

**Statistical analysis**

All the experiments were repeated for 5 times and results were represented as the mean ± standard deviation. Differences between groups were examined by one-way analysis of variance and t test in SPSS 20 (IBM, New York, USA). \( P < 0.05 \) was considered statistically significant.

**Results**

**Chondrocyte apoptosis and NR4A1 expression are promoted during OA**

To start with, we examined the cartilage sections of and performed *in situ* TUNEL assay to assess chondrocyte apoptosis in OA and normal cartilage. More FITC-positive cells were observed in OA cartilage sections than normal sections and significant difference was found when all the patients were examined (\( P < 0.01 \), Figure 1), which indicated elevated chondrocyte apoptosis during OA.

Then mRNA and protein levels of NR4A1 were detected in normal and OA cartilage samples. qRT-PCR results showed that NR4A1 mRNA expression was significantly higher in OA tissues than control (\( P < 0.05 \), Figure 2A), and western blot showed similar NR4A1 protein expression pattern which was obviously elevated in OA cartilage (\( P < 0.05 \), Figure 2B). We assumed that there might be possible associations between the elevated chondrocyte apoptosis and the promoted NR4A1 expression, which were to be analyzed in the following experiments.

**NR4A1 co-locates with mitochondria and BCL2 during OA**

Immunohistofluorescence was performed to detect the localization of NR4A1 in chondrocytes. Results showed that in chondrocytes of normal cartilage, NR4A1 signals were located in nuclei, overlapping DAPI signals. But in the chondrocytes of OA patients, most NR4A1 signals were located to cytoplasm and seemed to overlap PHB signals which indicated mitochondria (Figure 3A). BCL2, an important factor in mitochondrial apoptosis pathway, was also labelled by fluorescence, and consistent results were observed that NR4A1 signals in normal chondrocytes were translocated to cytoplasm.

![Figure 2](image_url)  
**Figure 2.** NR4A1 expression is promoted during OA. A. NR4A1 mRNA level detected by qRT-PCR. B. NR4A1 protein level detected by western blot and the histogram drawn based on repeated results. The experiments are repeated five times. *P < 0.05. OA, osteoarthritis. NR4A1, nuclear subfamily 4, group A, member 1.
NR4A1 is a target for treating OA

co-localizing with BCL2 (Figure 3B). These results indicated that NR4A1 was translocated to cytoplasm and localized to mitochondria during OA, which implied the involvement of NR4A1 in mitochondria apoptosis pathway.

NR4A1 and p38 is involved in TNF-induced apoptosis

Based on the above results, we suspected that the promoted expression of NR4A1 chondrocytes might be related to elevated inflammatory factors during OA. Here TNF and IL6 were used to treat cultured chondrocytes for their possible involvement in chondrocyte apoptosis during OA [19, 20]. Results showed that after 12 or 24 h of treatment, both IL6 and TNF promoted NR4A1 protein level in cultured chondrocytes from normal cartilage, with a time-dependent manner (Figure 4), implying that NR4A1 might be induced by inflammatory cytokines like IL6 and TNF during OA.

Figure 3. Localization of NR4A1 in normal and OA patients. A. NR4A1 (green) is translocated to cytoplasm and co-localized with PHB-marked mitochondria (red) in OA patients. B. NR4A1 (red) is translocated to cytoplasm and co-localized with BCL2 (green) in OA patients. Immunohistofluorescence is performed in normal and OA cartilage sections and in each section NR4A1 and PHB or BCL2 are marked with the specific primary antibodies and then the secondary antibodies labelled by Alexa Fluor 647 (red) or 488 (green). DAPI stains nuclei. The experiments are repeated five times. Bar indicates 10 μm. OA, osteoarthritis. NR4A1, nuclear receptor subfamily 4, group A, member 1. PHB, prohibitin. BCL2, B-cell lymphoma 2. merge, pictures showing green, red and blue signals at the same time.
NR4A1 is a target for treating OA

We used TNF to represent typical inflammatory cytokines and treated the cultured chondrocytes for 12 h which were then transfected with si-NR4A1 or scramble siRNA. Cleaved PARP1 protein was used as an indicator of cell apoptosis and western blot showed that si-NR4A1 transfection successfully inhibited NR4A1 protein level, and that TNF treatment could increase cleaved PARP1 level. But the change in cleaved PARP1 change was not that obvious when NR4A1 was knocked down (Figure 5A).

We further tested cell apoptosis via TUNEL assay and calculated the apoptotic cell percent in each sample, and results showed similar changes to the cleaved PARP1 (Figure 5B): TNF significantly induced cell apoptosis with or without the knockdown of NR4A1 (P < 0.001 or P < 0.01), and the increased cell apoptosis was obviously suppressed, but not totally abrogated, when NR4A1 was knocked down (P < 0.05). It could be deduced that the TNF-induced chondrocyte apoptosis might partly rely on NR4A1 or NR4A1-mediated pathways.

Discussion

Nuclear orphan receptor NR4A1 has not been reported in the regulation of chondrocytes or...
OA. This study reveals the up-regulation of NR4A1 and its translocation to mitochondria in joint cartilage chondrocytes of OA patients. NR4A1 expression is promoted by TNF treatment in cultured chondrocytes, which is involved in TNF-induced cell apoptosis. Further, we find the up-regulated NR4A1 by TNF is partly dependent on p38 MAPK.

OA is accompanied by increased chondrocyte apoptosis in joint cartilage, which was supported by TUNEL assay in this study on ten OA patients and ten non-OA patients. We then observed that the NR4A1 expression level in these OA cartilages was significantly higher than in normal samples. Actually, the up-regulation of NR4A1 has been reported in diseases like B-cell lymphomas, where its proapoptotic functions inhibit lymphomagenesis [25]. So the results of this study led us to hypothesize the involvement and possible mechanism of NR4A1 in modulating chondrocyte apoptosis.

The location of NR4A1 was labelled in normal and OA cartilage sections and we observed the translocation of NR4A1 to mitochondria, co-locating with BCL2 during OA. Mitochondrial proteins hold vital positions in chondrocyte apoptosis, with over 20 proteins aberrantly expressed during OA [26]. NR4A1 is capable of responding to apoptotic stimuli, translocating from the nucleus to mitochondria and inducing the release of cytochrome c and cell apoptosis [27]. In the process, NR4A1 recruits and interacts with key apoptotic factors in BCL2 family, such as BCL2, BAX and NIX, to participate in mitochondrial apoptosis pathway [13, 28-30]. Based on the existed information, it can be deduced that the up-regulated NR4A1 in OA chondrocytes is translocated to mitochondria, which allows NR4A1 to interact with BCL2 or other apoptotic factors to activate mitochondrial apoptosis pathway and further induce chondrocyte apoptosis during OA.

Mitochondrial dysfunction can be generated from mitochondrial DNA (mtDNA) mutation or proinflammatory mediators such as cytokines, prostaglandins, ROS and nitric oxide (NO) [31]. Proinflammatory factors like TNF may damage mtDNA, interrupt mitochondrial functions including energy production and mitochondrial transcription, and lead to chondrocyte apoptosis in OA [32]. Consistent to these reports, this study detected elevated chondrocyte apoptosis after TNF treatment and found this process was partly dependent on the elevated NR4A1. So NR4A1 is a likely subsidiary in TNF-induced chondrocyte apoptosis during OA.

Existing studies indicate the pivotal position of MAPK pathways in heat or mechanical stress and NO-induced articular chondrocyte apoptosis [33, 34]. Moreover, MAPK pathways including p38, extracellular signal-regulated kinase and JNK MAPK are important mediators for TNF-induced cell apoptosis [35-37]. This study also tried to investigate the niche of MAPK pathways during the up-regulation of NR4A1 by TNF, and the relative expression results showed that p38, rather than JNK, was partly involved in the promoted NR4A1 by TNF. All information considered, it is deduced that p38 MAPK is one of the possible pathways mediating TNF-induced NR4A1, and that TNF/p38/NR4A1 signaling and NR4A1-involved mitochondrial apoptosis pathway are possible mechanisms in OA chondrocyte apoptosis.

In summary, NR4A1 is up-regulated in joint cartilage chondrocytes of OA patients. NR4A1 can be induced by cytokines like TNF and promote chondrocyte apoptosis in association with p38 MAPK and mitochondrial apoptosis pathway. These results offer a potential target for OA treatment and further mechanism investigation is necessary for controlling OA.

Acknowledgements

Construction and clinical application of digital precision spinal surgery system, major scientific and technological research of Henan provincial science and technology department in 2015 (No. 162102310018).

Disclosure of conflict of interest

None.

Address correspondence to: Yanzheng Gao, Department of Orthopedics, Henan Provincial People’s Hospital, No. 5, Weiwu Road, Zhengzhou 450003, Henan, China. E-mail: gaoyanzheng123@126.com

References

NR4A1 is a target for treating OA


[16] Schuerwegh AJ, Dombrecht EJ, Stevens WJ, Van Offel JF, Brdts CH and De Clerck LS. Influence of pro-inflammatory (IL-1α, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL4) cytokines on chondrocyte function. Osteoarthritis Cartilage 2003; 11: 681-687.


NR4A1 is a target for treating OA

targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 2006; 118: 112-121.


